Monrovia, CA, United States of America

Roslyn Ray

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Beckman Research Institute, City of Hope. Active years: 2022.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Roslyn Ray: Innovator in Hypercholesterolemia Treatment

Introduction

Roslyn Ray is a prominent inventor based in Monrovia, CA (US). She has made significant contributions to the field of medical research, particularly in the treatment of hypercholesterolemia. Her innovative work has led to the development of novel compositions and methods that aim to improve health outcomes for individuals suffering from this condition.

Latest Patents

Roslyn Ray holds 1 patent for her invention titled "Compositions and methods for the treatment of hypercholesterolemia." This patent describes compositions that include double-stranded and single-stranded RNAs capable of repressing IncRNA while simultaneously increasing LDLR activation. These compositions are particularly useful for activating LDLR in liver cells, providing a potential therapeutic avenue for managing cholesterol levels.

Career Highlights

Roslyn Ray is affiliated with the Beckman Research Institute, City of Hope, where she conducts her research. Her work is characterized by a commitment to advancing medical science and improving patient care through innovative solutions.

Collaborations

One of her notable collaborators is Kevin V Morris, with whom she has worked closely on various research projects. Their partnership exemplifies the collaborative spirit that drives innovation in the scientific community.

Conclusion

Roslyn Ray's contributions to the treatment of hypercholesterolemia highlight her role as a leading inventor in the medical field. Her innovative approaches and dedication to research continue to pave the way for advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…